metformin has been researched along with Pulmonary Disease, Chronic Obstructive in 21 studies
Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289)
metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.
Pulmonary Disease, Chronic Obstructive: A disease of chronic diffuse irreversible airflow obstruction. Subcategories of COPD include CHRONIC BRONCHITIS and PULMONARY EMPHYSEMA.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Metformin is associated with improved respiratory outcomes in asthma; however, metformin in COPD and asthma-COPD overlap (ACO) remains unexplored." | 9.41 | Metformin use and respiratory outcomes in asthma-COPD overlap. ( Bon, J; Fawzy, A; Hansel, NN; Kinney, GL; McCormack, MC; Neupane, M; Putcha, N; Tejwani, V; Wise, RA; Wu, TD, 2021) |
| "Among 4231 COPD patients, 556 (13%) had DM, and these patients had 1." | 5.51 | Metformin use mitigates the adverse prognostic effect of diabetes mellitus in chronic obstructive pulmonary disease. ( Ho, TW; Huang, CT; Lai, F; Lien, AS; Tsai, YJ; Yu, CJ, 2019) |
| "Metformin users were younger, were less sick, were less likely to be on oxygen, and had fewer hospitalizations in the prior year compared with the nonusers." | 5.48 | Metformin use and health care utilization in patients with coexisting chronic obstructive pulmonary disease and diabetes mellitus. ( Bishwakarma, R; Cardenas, VJ; Kuo, YF; Lin, YL; Sharma, G; Zhang, W, 2018) |
| "Metformin is associated with improved respiratory outcomes in asthma; however, metformin in COPD and asthma-COPD overlap (ACO) remains unexplored." | 5.41 | Metformin use and respiratory outcomes in asthma-COPD overlap. ( Bon, J; Fawzy, A; Hansel, NN; Kinney, GL; McCormack, MC; Neupane, M; Putcha, N; Tejwani, V; Wise, RA; Wu, TD, 2021) |
| " One possible modulator of ENaC is AMP-activated protein kinase (AMPK), a key molecule that controls a wide variety of cellular signals; however, little is known about whether metformin, a clinically available AMPK activator, has a protective role against ENaC-associated chronic pulmonary phenotypes, such as emphysema and pulmonary dysfunction." | 4.12 | Metformin suppresses epithelial sodium channel hyperactivation and its associated phenotypes in a mouse model of obstructive lung diseases. ( Eto, Y; Fujikawa, H; Hayashi, M; Kai, H; Kamei, S; Kawakami, T; Kishimoto, T; Maruta, K; Nakashima, R; Nasu, A; Nohara, H; Shuto, T; Suico, MA; Takahashi, N; Ueno-Shuto, K, 2022) |
| " However, due to its rare association with lactic acidosis, its safety in COPD is uncertain." | 3.81 | Safety of metformin in patients with chronic obstructive pulmonary disease and type 2 diabetes mellitus. ( Archer, JR; Baker, EH; Hitchings, AW; Srivastava, SA, 2015) |
| "Metformin is a well-established anti-hyperglycaemic agent in diabetes mellitus, possibly augmented with anti-inflammatory effects, but its effects in COPD are unknown." | 2.82 | Metformin in severe exacerbations of chronic obstructive pulmonary disease: a randomised controlled trial. ( Baker, EH; Hitchings, AW; Jones, PW; Lai, D, 2016) |
| "Participants with moderate or severe COPD, BMI > 25 kg/m(2), and type 2 diabetes mellitus or impaired glucose tolerance took metformin twice daily for 6 months." | 2.79 | Respiratory effects of insulin sensitisation with metformin: a prospective observational study. ( Kolbe, J; Metcalf, P; Sexton, P, 2014) |
| "Although current therapies in chronic obstructive pulmonary disease (COPD) improve the quality of life, they do not satisfactorily reduce disease progression or mortality." | 2.55 | Geroprotectors as a therapeutic strategy for COPD - where are we now? ( Białas, AJ; Górski, P; Makowska, J; Miłkowska-Dymanowska, J; Piotrowski, WJ; Wardzynska, A, 2017) |
| "Chronic obstructive pulmonary disease (COPD) is a chronic inflammatory disease of the lungs, which progresses very slowly and the majority of patients are therefore elderly." | 2.50 | STOP accelerating lung aging for the treatment of COPD. ( Ito, K; Mercado, N, 2014) |
| "We studied whether in patients with COPD the use of metformin for diabetes treatment was linked to a pattern of lung function decline consistent with the hypothesis of anti-aging effects of metformin." | 1.72 | Reduced decline of lung diffusing capacity in COPD patients with diabetes and metformin treatment. ( Alter, P; Andreas, S; Bals, R; Behr, J; Frankenberger, M; Jörres, RA; Kahnert, K; Kellerer, C; Lehmann, M; Lucke, T; Lutter, JI; Seissler, J; Trudzinski, FC; Vogelmeier, CF; Watz, H; Welte, T; Yildirim, Ö, 2022) |
| " Metformin use also exhibited significant dose-response relationship with respect to the risks of bacterial pneumonia, hospitalization for COPD and IMV." | 1.56 | Respiratory outcomes of metformin use in patients with type 2 diabetes and chronic obstructive pulmonary disease. ( Hsu, CC; Hwu, CM; Wei, JC; Yang, YC; Yen, FS, 2020) |
| "Exacerbation of chronic obstructive pulmonary disease (COPD) severely impacts the quality of life and causes high mortality and morbidity." | 1.56 | Use of antidiabetic medications and risk of chronic obstructive pulmonary disease exacerbation requiring hospitalization: a disease risk score-matched nested case-control study. ( Huang, YL; Kuo, FC; Lai, JH; Tsai, CL; Tu, MY; Wang, MT; Wang, YH, 2020) |
| "A reduced risk of COPD is observed in metformin users with T2D." | 1.51 | Metformin and risk of chronic obstructive pulmonary disease in diabetes patients. ( Tseng, CH, 2019) |
| "Among 4231 COPD patients, 556 (13%) had DM, and these patients had 1." | 1.51 | Metformin use mitigates the adverse prognostic effect of diabetes mellitus in chronic obstructive pulmonary disease. ( Ho, TW; Huang, CT; Lai, F; Lien, AS; Tsai, YJ; Yu, CJ, 2019) |
| "Metformin users were younger, were less sick, were less likely to be on oxygen, and had fewer hospitalizations in the prior year compared with the nonusers." | 1.48 | Metformin use and health care utilization in patients with coexisting chronic obstructive pulmonary disease and diabetes mellitus. ( Bishwakarma, R; Cardenas, VJ; Kuo, YF; Lin, YL; Sharma, G; Zhang, W, 2018) |
| "COPD is a known risk factor for incident T2DM, however few studies have examined the relationship in reverse." | 1.48 | Type 2 diabetes: A protective factor for COPD? ( Correa, A; Creagh-Brown, B; de Lusignan, S; Gatenby, P; McGovern, AP; Rayner, LH; Sherlock, J, 2018) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 16 (76.19) | 24.3611 |
| 2020's | 5 (23.81) | 2.80 |
| Authors | Studies |
|---|---|
| Kahnert, K | 1 |
| Andreas, S | 1 |
| Kellerer, C | 1 |
| Lutter, JI | 1 |
| Lucke, T | 1 |
| Yildirim, Ö | 1 |
| Lehmann, M | 1 |
| Seissler, J | 1 |
| Behr, J | 1 |
| Frankenberger, M | 1 |
| Bals, R | 1 |
| Watz, H | 1 |
| Welte, T | 1 |
| Trudzinski, FC | 1 |
| Vogelmeier, CF | 1 |
| Alter, P | 1 |
| Jörres, RA | 1 |
| Nakashima, R | 1 |
| Nohara, H | 1 |
| Takahashi, N | 1 |
| Nasu, A | 1 |
| Hayashi, M | 1 |
| Kishimoto, T | 1 |
| Kamei, S | 1 |
| Fujikawa, H | 1 |
| Maruta, K | 1 |
| Kawakami, T | 1 |
| Eto, Y | 1 |
| Ueno-Shuto, K | 1 |
| Suico, MA | 1 |
| Kai, H | 1 |
| Shuto, T | 1 |
| Yen, FS | 2 |
| Wei, JC | 2 |
| Yang, YC | 1 |
| Hsu, CC | 2 |
| Hwu, CM | 2 |
| Wang, MT | 1 |
| Lai, JH | 1 |
| Huang, YL | 1 |
| Kuo, FC | 1 |
| Wang, YH | 1 |
| Tsai, CL | 1 |
| Tu, MY | 1 |
| Wu, TD | 1 |
| Fawzy, A | 1 |
| Kinney, GL | 1 |
| Bon, J | 1 |
| Neupane, M | 1 |
| Tejwani, V | 1 |
| Hansel, NN | 1 |
| Wise, RA | 1 |
| Putcha, N | 1 |
| McCormack, MC | 1 |
| Miłkowska-Dymanowska, J | 1 |
| Białas, AJ | 1 |
| Makowska, J | 1 |
| Wardzynska, A | 1 |
| Górski, P | 1 |
| Piotrowski, WJ | 1 |
| Bishwakarma, R | 1 |
| Zhang, W | 1 |
| Lin, YL | 1 |
| Kuo, YF | 1 |
| Cardenas, VJ | 1 |
| Sharma, G | 1 |
| Cui, W | 1 |
| Zhang, Z | 1 |
| Zhang, P | 1 |
| Qu, J | 1 |
| Zheng, C | 1 |
| Mo, X | 1 |
| Zhou, W | 1 |
| Xu, L | 1 |
| Yao, H | 1 |
| Gao, J | 1 |
| Tseng, CH | 1 |
| Rayner, LH | 1 |
| McGovern, AP | 1 |
| Sherlock, J | 1 |
| Gatenby, P | 1 |
| Correa, A | 1 |
| Creagh-Brown, B | 1 |
| de Lusignan, S | 1 |
| Sirois, C | 1 |
| Lunghi, C | 1 |
| Laroche, ML | 1 |
| Maheux, A | 1 |
| Frini, A | 1 |
| Chen, W | 1 |
| Ho, TW | 1 |
| Huang, CT | 1 |
| Tsai, YJ | 1 |
| Lien, AS | 1 |
| Lai, F | 1 |
| Yu, CJ | 1 |
| Sexton, P | 1 |
| Metcalf, P | 1 |
| Kolbe, J | 1 |
| Ito, K | 1 |
| Mercado, N | 1 |
| Yasar, Z | 1 |
| Erdem, F | 1 |
| Talay, F | 1 |
| He, LR | 1 |
| Qiao, W | 1 |
| Liao, ZX | 1 |
| Komaki, R | 1 |
| Ho, L | 1 |
| Hofstetter, WL | 1 |
| Lin, SH | 1 |
| Hitchings, AW | 3 |
| Archer, JR | 1 |
| Srivastava, SA | 1 |
| Baker, EH | 3 |
| Lai, D | 1 |
| Jones, PW | 2 |
| Man, SF | 1 |
| Sin, DD | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Genetic Epidemiology of Chronic Obstructive Pulmonary Disease[NCT00608764] | 10,718 participants (Actual) | Observational | 2007-11-30 | Active, not recruiting | |||
| A Randomised, Double-blind, Placebo-controlled Trial of Metformin in Chronic Obstructive Pulmonary Disease (COPD) Exacerbations: a Pilot Study[NCT01247870] | Phase 4 | 52 participants (Actual) | Interventional | 2011-01-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for metformin and Pulmonary Disease, Chronic Obstructive
| Article | Year |
|---|---|
Geroprotectors as a therapeutic strategy for COPD - where are we now?
Topics: Aging; Disease Progression; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Me | 2017 |
STOP accelerating lung aging for the treatment of COPD.
Topics: Aging; Disease Progression; Humans; Inflammation; Lung; Metformin; Oxidative Stress; Pulmonary Disea | 2014 |
4 trials available for metformin and Pulmonary Disease, Chronic Obstructive
| Article | Year |
|---|---|
Metformin use and respiratory outcomes in asthma-COPD overlap.
Topics: Adult; Aged; Asthma; Cohort Studies; Comorbidity; Cross-Sectional Studies; Female; Follow-Up Studies | 2021 |
Respiratory effects of insulin sensitisation with metformin: a prospective observational study.
Topics: Adult; Aged; Body Mass Index; Diabetes Mellitus, Type 2; Dyspnea; Exercise Tolerance; Female; Hand S | 2014 |
Metformin in severe exacerbations of chronic obstructive pulmonary disease: a randomised controlled trial.
Topics: Adult; Aged; Blood Glucose; C-Reactive Protein; Disease Progression; Double-Blind Method; Female; Fr | 2016 |
Handling missing items in the Exacerbations of Chronic Pulmonary Disease Tool.
Topics: Adult; Diagnostic Self Evaluation; Female; Humans; Hypoglycemic Agents; Male; Metformin; Pulmonary D | 2016 |
15 other studies available for metformin and Pulmonary Disease, Chronic Obstructive
| Article | Year |
|---|---|
Reduced decline of lung diffusing capacity in COPD patients with diabetes and metformin treatment.
Topics: Age Factors; Aged; Body Mass Index; Cohort Studies; Diabetes Mellitus; Female; Forced Expiratory Vol | 2022 |
Metformin suppresses epithelial sodium channel hyperactivation and its associated phenotypes in a mouse model of obstructive lung diseases.
Topics: AMP-Activated Protein Kinases; Animals; Disease Models, Animal; Emphysema; Epithelial Sodium Channel | 2022 |
Respiratory outcomes of metformin use in patients with type 2 diabetes and chronic obstructive pulmonary disease.
Topics: Adult; Aged; Diabetes Mellitus, Type 2; Female; Follow-Up Studies; Hospitalization; Humans; Hypoglyc | 2020 |
Use of antidiabetic medications and risk of chronic obstructive pulmonary disease exacerbation requiring hospitalization: a disease risk score-matched nested case-control study.
Topics: Administration, Oral; Aged; Aged, 80 and over; Case-Control Studies; Databases, Factual; Diabetes Me | 2020 |
Metformin use and health care utilization in patients with coexisting chronic obstructive pulmonary disease and diabetes mellitus.
Topics: Administrative Claims, Healthcare; Aged; Aged, 80 and over; Chi-Square Distribution; Comorbidity; Da | 2018 |
Nrf2 attenuates inflammatory response in COPD/emphysema: Crosstalk with Wnt3a/β-catenin and AMPK pathways.
Topics: AMP-Activated Protein Kinases; Animals; beta Catenin; Bronchi; Bronchoalveolar Lavage Fluid; Emphyse | 2018 |
Metformin and risk of chronic obstructive pulmonary disease in diabetes patients.
Topics: Aged; Databases, Factual; Diabetes Mellitus, Type 2; Female; Humans; Incidence; Male; Metformin; Mid | 2019 |
Type 2 diabetes: A protective factor for COPD?
Topics: Adult; Aged; Aged, 80 and over; Comorbidity; Diabetes Mellitus, Type 2; England; Female; Humans; Hyp | 2018 |
The delicate choice of optimal basic therapy for multimorbid older adults: A cross-sectional survey.
Topics: Adrenergic beta-Agonists; Adrenergic beta-Antagonists; Aged; Angiotensin Receptor Antagonists; Angio | 2019 |
Effects of metformin use on total mortality in patients with type 2 diabetes and chronic obstructive pulmonary disease: A matched-subject design.
Topics: Adult; Aged; Cause of Death; Cohort Studies; Diabetes Mellitus, Type 2; Emergency Medical Services; | 2018 |
Metformin use mitigates the adverse prognostic effect of diabetes mellitus in chronic obstructive pulmonary disease.
Topics: Aged; Aged, 80 and over; Cohort Studies; Comorbidity; Diabetes Mellitus; Female; Humans; Hypoglycemi | 2019 |
Benefit of Metformin in COPD: An Effect on Autonomic Nervous System?
Topics: Autonomic Nervous System; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Metformin; Pulmona | 2015 |
Impact of comorbidities and use of common medications on cancer and non-cancer specific survival in esophageal carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Angiotensin Receptor Antagonists; Anti-Inflammatory Agents, Non-Ster | 2015 |
Safety of metformin in patients with chronic obstructive pulmonary disease and type 2 diabetes mellitus.
Topics: Acidosis, Lactic; Adult; Aged; Aged, 80 and over; Biomarkers; Diabetes Mellitus, Type 2; Female; Hum | 2015 |
Could oral hypoglycemics be the new therapeutic answer to chronic obstructive pulmonary disease?
Topics: Administration, Oral; Diabetes Mellitus; Forced Expiratory Volume; Humans; Hypoglycemic Agents; Metf | 2010 |